5-year follow-up after focal therapy with HIFU for localized prostate cancer

A new paper from the Emberton-Ahmed group in the UK has reported 5-year follow-up data from a cohort of > 600 patients with clinically significant, localized prostate cancer, all treated with focal forms of high-intensity focused ultrasound (HIFU). … READ MORE …

More reports from the EAU “Update on Prostate Cancer”

Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …

Salvage focal ablation for radio-recurrent prostate cancer

When there is a recurrence after primary radiation treatment, it is very tempting to try to identify the site(s) of local recurrence within the prostate and prostate bed and only treat those. The hope is that we can destroy any remaining cancer while keeping toxicity to the bladder, rectum, and neurovascular bundles to a minimum. … READ MORE …

A pathological “take” on the potential role of focal therapy

Various forms of focal therapy are now being used by some physicians to treat selected patients with well-identified, usually relatively small, “dominant” or “index” tumors that are confined to highly defined areas of the prostate. … READ MORE …

CureTalk on focal laser ablation therapy for prostate cancer

Last Tuesday, through the CureTalks service, we held an hour-long discussion with Dr. Ara Karamanian about the evolving and potential role of focal laser ablation (FLA) in the management of prostate cancer. … READ MORE …

Focal laser ablation — a CureTalk discussion

At 6:00 p.m. this evening, Eastern Time, here in the USA, we will be collaborating with our friends at CureTalks to provide an introduction to focal laser ablation in the treatment of prostate cancer. To sign up, to listen in, or ask questions, please click here. … READ MORE …

Yet another new type of HIFU is now in Phase II clinical trials

Another breathless media release has announced enrollment of the first patient into a Phase II clinical trial of yet another new form of high-intensity, focused ultrasound (HIFU) in men with low-risk and favorable, intermediate-risk, localized prostate cancer. … READ MORE …